Mohsenifar Jaleh, Almassi-Aghdam Maryam, Mohammad-Taheri Zohreh, Zare Khandan, Jafari Bahar, Atri Morteza, Mortazavi Seyed-Hossein, Azadeh Payam, Bagherzadeh Mostafa, Azargashb Eznollah, Rahimi Farzaneh
Department of Pathology, Taleghani Hospital, Shaheed Beheshti University of Medical Sciences, Tehran, Iran.
Arch Iran Med. 2007 Jan;10(1):27-31.
Breast cancer is the leading cause of carcinoma death in women. Proper treatment depends on the consideration of molecular biology status of tumor cells, which may determine the patient's treatment and prognosis. To determine the prognostic models for this disease, we evaluated the role of cell proliferation-related antigens including ki-67 (a nuclear antigen, expressed in G1, G2, and M phases of cell cycle) and repp86 (an 86-kDa nuclear protein expressed in S, G2, and M phases of cell cycle) for detection of biologic behavior of breast cancer.
We studied 60 women with grade I and II lymph node-negative and 27 with grade III lymph node-positive breast cancers. The mean follow-up periods for these two groups were 60 and 72 months, respectively. Tumor cell proliferation was measured by immunohistochemical methods with monoclonal antibodies directed against the nuclear antigens ki-67 and repp86.
The ki-67, repp86 labeling indices (percentage of antibody-stained tumor cell nuclei) were not statistically different between the cases and controls of lymph node-negative patients (ki-67 with P = 0.33; repp86 with P = 0.40). The odds ratio (the mean chance of ki-67 labeling index > 10%, repp86 labeling index >10%) in patients with recurrence was 4 (CI = 0.2 - 76.5) for ki-67 and 3.6 (CI = 0.4 - 32.5) for repp86. Both indices were statistically different in lymph node-positive cases and controls (P < 0.0001). The odds ratio in patients with recurrence was 87 (CI = 4 - 18.71) for ki-67 and 71.5 (CI = 5.7 - 899.2) for repp86.
The present study confirms the importance of cell proliferation as a determinant of biologic behavior of breast cancer. Measurement of ki-67 and repp86 labeling indices may be very helpful for physicians to detect high-risk patients and to adopt appropriate procedure such as adjuvant therapy.
乳腺癌是女性癌症死亡的主要原因。恰当的治疗取决于对肿瘤细胞分子生物学状态的考量，这可能决定患者的治疗方案和预后。为确定该疾病的预后模型，我们评估了细胞增殖相关抗原的作用，包括ki-67（一种核抗原，在细胞周期的G1、G2和M期表达）和repp86（一种86 kDa的核蛋白，在细胞周期的S、G2和M期表达）在检测乳腺癌生物学行为中的作用。
我们研究了60例I级和II级淋巴结阴性的乳腺癌女性患者以及27例III级淋巴结阳性的乳腺癌患者。这两组的平均随访期分别为60个月和72个月。采用针对核抗原ki-67和repp86的单克隆抗体，通过免疫组化方法测量肿瘤细胞增殖情况。
在淋巴结阴性患者的病例组和对照组之间，ki-67、repp86标记指数（抗体染色肿瘤细胞核的百分比）无统计学差异（ki-67，P = 0.33；repp86，P = 0.40）。复发患者中，ki-67标记指数>10%、repp86标记指数>10%的比值比分别为4（CI = 0.2 - 76.5）和3.6（CI = 0.4 - 32.5）。在淋巴结阳性病例组和对照组中，这两个指数均有统计学差异（P < 0.0001）。复发患者中，ki-67的比值比为87（CI = 4 - 18.71），repp86的比值比为71.5（CI = 5.7 - 899.2）。
本研究证实了细胞增殖作为乳腺癌生物学行为决定因素的重要性。测量ki-67和repp86标记指数可能对医生检测高危患者并采取适当措施（如辅助治疗）非常有帮助。
